{"nctId":"NCT01606007","briefTitle":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","startDateStruct":{"date":"2012-07"},"conditions":["Type 2 Diabetes"],"count":1282,"armGroups":[{"label":"Arm 1: Saxagliptin+Metformin XR+Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Saxagliptin","Drug: Metformin XR","Drug: Placebo matching with Dapagliflozin"]},{"label":"Arm 2: Dapagliflozin+Metformin XR+Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin XR","Drug: Dapagliflozin","Drug: Placebo matching with Saxagliptin"]},{"label":"Arm 3: Saxagliptin+Dapagliflozin+Metformin XR","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Metformin XR","Drug: Dapagliflozin"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Metformin XR","otherNames":["Glucophage XR"]},{"name":"Dapagliflozin","otherNames":["BMS-512148"]},{"name":"Placebo matching with Dapagliflozin","otherNames":[]},{"name":"Placebo matching with Saxagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with Type 2 diabetes mellitus (T2DM) with HbA1c ≥ 8.0% and ≤ 12.0%\n* Stable metformin therapy dose of ≥ 1500mg for at least 8 weeks prior to screening\n* Body mass index (BMI) ≤ 45.0kg/m2\n\nExclusion Criteria:\n\n* Estimated glomerular filtration rate (eGFR) \\< 60mL/min/1,73m2 and Serum Creatinine (Scr) ≥ 1.5 mg/dL in males or ≥ 1.4 mg/dL in females\n* Uncontrolled hypertension Systolic Blood Pressure (SBP) ≥ 160mmHg and/or Diastolic Blood Pressure (DBP) ≥ 100mmHg\n* Hepatic disease\n* Cardiovascular disease within 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24","description":"HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained at Week 24 in the double-blind period, including observations prior to rescue.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":null},{"groupId":"OG001","value":"-1.20","spread":null},{"groupId":"OG002","value":"-1.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])","description":"Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. PPG measurements were obtained at week 24 in the doubleblind period, including observations prior to rescue.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"3.510"},{"groupId":"OG001","value":"-70.4","spread":"3.538"},{"groupId":"OG002","value":"-79.6","spread":"3.426"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":null},{"groupId":"OG001","value":"-31.7","spread":null},{"groupId":"OG002","value":"-37.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","description":"Therapeutic glycemic response is defined as HbA1c \\<7.0%. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"41.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in Body Weight at Week 24","description":"Baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight measurements were obtained at Week 24 in the doubleblind period, including observations prior to rescue.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"-2.39","spread":null},{"groupId":"OG002","value":"-2.05","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":176},"commonTop":[]}}}